News Releases

MCC logo

MINNEAPOLIS, MN- November 19, 2020 -The University of Minnesota has become the first location in the world for a new innovative clinical trial for the treatment of acute myelogenous leukemia (AML) and multiple myeloma. The Phase 1 clinical trial for FT538 will eventually be a multicenter study but has initially opened exclusively at the M Health Fairview University of Minnesota Medical Center. 

blaes and brunstein

Dr. Anne Blaes has accepted the role of co-leader of the Screening, Prevention, Etiology and Cancer Survivorship (SPECS) Research Program at the Masonic Cancer Center, University of Minnesota. Blaes is an Associate Professor of Medicine with the University of Minnesota Medical School’s Division of Hematology, Oncology, and Transplantation and the Director of Cancer Survivorship Research.

Robert Kratzke

MINNEAPOLIS, MN- Nov. 9, 2020 - The University of Minnesota, which is already at the forefront of COVID-19 research, has opened a new trial to study the short and long-term effects of the novel coronavirus on cancer patients. The study is a partnership between the Masonic Cancer Center, University of Minnesota, and the National Cancer Institute (NCI).

Ilana Chefetz

Institute researchers find evidence in favor of necroptotic therapies

November 2, 2020 (Austin, Minn.) – Dr. Ilana Chefetz, head of the Cancer Stem Cells & Necroptosis lab at The Hormel Institute, published a review article focusing on a specific type of cell death called “necroptosis” and its possible role in eliminating tumors that are resistant to chemotherapy.

a

Discoveries may impact future brain tumor therapy and treatment for hospital-acquired infections

October 27, 2020 (Austin, Minn.) –  The Nucleotide Metabolism & Drug Discovery lab at The Hormel Institute, led by Dr. Jarrod French, recently published three research papers in major scientific journals. The articles detail the research group’s work on two classes of photoreceptor proteins activated by blue light. 

Credit: nicolas_

MINNEAPOLIS, MN - The University of Minnesota has opened a new and innovative clinical trial for the treatment of metastatic gastrointestinal epithelial cancer. The Phase I/II clinical trial, which will use the revolutionary CRISPR/Cas9 System, has opened exclusively at the M Health Fairview University of Minnesota Medical Center. 

MCC logo

Leaders in the Program in Health Disparities Research (PHDR) and the Masonic Cancer Center, University of Minnesota recently received a $2,063,688 award from the National Cancer Institute/National Institutes of Health for their R25 project, “Minnesota Advancing Science, Enhancing Diversity: M-ASCEND.” 

Dr. Holtan

MINNEAPOLIS, MN - The FDA has granted Orphan Drug Designation to urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF, most commonly available as Pregnyl®) for the treatment of acute graft-versus-host-disease (GVHD). This designation will expedite the development and review of uhCG in treating acute GVHD, a potentially life-threatening complication following a hematopoietic cell transplant.

Pages